Full-Time
Senior Manager
Financial Business Partnering
Posted on 7/2/2025
Icon
10,001+ employees
Consulting and development services for pharmaceuticals
No salary listed
Senior
Chennai, Tamil Nadu, India
In Person
- Degree in finance, accounting, or a related field; MBA or professional certification (CPA, CMA) is preferred.
- Extensive experience in financial business partnering, analysis, and reporting, ideally within the healthcare or clinical research sectors.
- Strong understanding of financial modeling, budgeting, and forecasting techniques.
- Exceptional analytical and problem-solving skills, with the ability to translate data into actionable insights.
- Excellent communication and interpersonal skills, with a proven ability to build relationships and influence stakeholders at all levels.
- Leading the financial business partnering function to provide comprehensive financial support and insights to business units.
- Collaborating with cross-functional teams to develop budgets, forecasts, and financial plans that align with organizational objectives.
- Conducting financial analysis to evaluate project performance and identify opportunities for cost savings and efficiencies.
- Preparing and presenting financial reports and recommendations to senior management and stakeholders.
- Mentoring and developing a team of financial analysts to enhance their skills and foster a high-performance culture.
Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon leverages a global network of experts who have experience across various therapeutic areas. This extensive expertise allows them to tailor their solutions to meet the specific needs of their clients, setting them apart from competitors who may not offer the same level of specialized support. The ultimate goal of Icon is to support the development of life-saving products that improve the quality of life for patients.
Company Size
10,001+
Company Stage
IPO
Headquarters
Ireland
Founded
1990
Simplify's Take
What believers are saying
- Increased use of AI accelerates clinical trial participant identification.
- Partnership with Mural Health enhances trial participant and site experience.
- Centre for Obesity expedites obesity-related clinical trials.
What critics are saying
- Complexity of multi-indication trials may lead to inefficiencies.
- Securities fraud lawsuit could cause financial and reputational damage.
- Underutilization of biomarkers may hinder optimization of neurodegenerative trials.
What makes Icon unique
- ICON offers a global network of offices in 53 countries.
- The company focuses on reducing time to market, cost, and increasing quality.
- ICON has extensive experience in a broad range of therapeutic areas.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Retirement Plan
Mental Health Support
Life Insurance
Flexible Work Hours
Company News
At Bio€quity Europe 2025, the premier investor conference for European biopharma, ICON was proud to contribute to the conversation shaping the future of early-stage innovation.
Alongside the whitepaper, ICON has launched their new Centre for Obesity that delivers expertise and market intelligence with a ready-to-deploy infrastructure of 100 sites and an in-development database of 10,000 pre-screened patients across the breadth of comorbidities related to obesity.
Dublin, Ireland – 7 May – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic RD for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% of respondents) are pursuing multi-indication approaches in their obesity-related research. However, the survey results also suggest that sponsors may underestimate the complexity of these strategies - particularly when selecting inclusion criteria and endpoints - which can lead to inefficiencies in the clinical development process
After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.
ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.